Alterity Therapeutics Limited (PBN) — Cash Flow-to-Debt Ratio
Alterity Therapeutics Limited (PBN) has a Cash Flow-to-Debt Ratio of -1.12x as of June 2023, meaning its operating cash flow of €-5.06 Million could theoretically repay -1% of its total liabilities (€4.50 Million) in one year. See working capital to net assets of Alterity Therapeutics Limited to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Alterity Therapeutics Limited Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Alterity Therapeutics Limited across 12 annual periods. Also explore PBN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Alterity Therapeutics Limited (2014–2025)
Year-by-year debt coverage analysis for Alterity Therapeutics Limited. For market capitalisation and broader financial context, see PBN company net worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.16x | €-11.45 Million | €3.62 Million | ▼ -36.0% |
| 2024 | -2.32x | €-12.61 Million | €5.43 Million | ▲ +47.8% |
| 2023 | -4.45x | €-20.04 Million | €4.50 Million | ▼ -112.5% |
| 2022 | -2.09x | €-12.34 Million | €5.89 Million | ▲ +62.4% |
| 2021 | -5.56x | €-17.33 Million | €3.12 Million | ▼ -62.6% |
| 2020 | -3.42x | €-9.43 Million | €2.76 Million | ▲ +17.8% |
| 2019 | -4.16x | €-13.95 Million | €3.36 Million | ▼ -76.1% |
| 2018 | -2.36x | €-6.25 Million | €2.64 Million | ▲ +36.0% |
| 2017 | -3.69x | €-5.87 Million | €1.59 Million | ▼ -17.2% |
| 2016 | -3.15x | €-7.42 Million | €2.36 Million | ▲ +21.2% |
| 2015 | -4.00x | €-10.87 Million | €2.72 Million | ▼ -16.7% |
| 2014 | -3.42x | €-13.54 Million | €3.95 Million | — |